Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
Crossref DOI link: https://doi.org/10.1186/s13045-017-0537-5
Published Online: 2017-11-02
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wang, Michael
Schuster, Stephen J.
Phillips, Tycel
Lossos, Izidore S.
Goy, Andre
Rule, Simon
Hamadani, Mehdi
Ghosh, Nilanjan
Reeder, Craig B.
Barnett, Evelyn
Bravo, Marie-Laure Casadebaig
Martin, Peter
Funding for this research was provided by:
Celgene Corporation